An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps

NCT07424144 · clinicaltrials.gov ↗

PHASE3

Phase

ENROLLING_BY_INVITATION

Status

380

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Rhinosinusitis With Nasal Polyps

Interventions

DRUG: Itepekimab (SAR440340)
DRUG: Placebo

Sponsor

Sanofi

Collaborators

[object Object]